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Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their
classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific disease entities,
although still have limited impact in tailoring the treatment. First-line treatment strategies can cure only a minority of patients and
relapsed-refractory disease still represents the major cause of failure. Frontline autologous transplantation may have an impact in the
consolidation of response; however, its role is still questioned as far as complete responses obtained after induction chemotherapy
are concerned. Newer drugs are now being evaluated in clinical trials, but effective salvage strategies for those who experience
treatment failures are lacking. Here we review and discuss the most controversial aspects of diagnosis and treatment of peripheral T-
cell lymphomas.Introduction
Peripheral T cell lymphomas (PTCL) comprise a heterogeneous
group of malignancies derived from mature T or natural killer
(NK) cells, representing less than 10% of all non-Hodgkin
lymphomas. With few exceptions, PTCL usually have an
aggressive course. There are about 30 PTCL entities in the
current World Health organization (WHO) classification of
lymphomas, grouped according to their clinical presentation into
predominantly leukemic, or as primarily nodal, extranodal or
cutaneous diseases.1 Diagnosing and managing PTCL is always
challenging: (i) it is still unclear whether certain biomarkers found
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approach to these diseases; (ii) responses to first-line treatment
are still unsatisfactory, given that PTCL frequently affect elderly
patients; (iii) we are still unsure about the impact of frontline
consolidation with autologous stem cell transplantation (ASCT)
in patients achieving a complete response (CR); (iv) although
several new drugs are emerging, we still lack an effective
salvage strategy for relapsing patients or those refractory to
chemotherapy.
This work is addressed to clarify the most controversial aspects
in the management of PTCL by presenting the current diagnostic
and treatment standards, as well as shedding light on potential
new drugs.Biopathology
Novel data derived from high-throughput genomic studies
have contributed to improve the definition of PTCL entities
(Table 1) and better understand their pathogenesis.2 Mutations
and copy number variations frequently target different classes of
epigenetic modifiers,3–6 T-cell receptor (TCR) and co-receptors
signaling pathways7–11 and, components or regulators of the
Janus kinase (JAK) signal transducer and activator of transcrip-
tion (STAT) pathway.12 Besides a few variants characteristic of
certain entities,7,13 there is overlap in the mutational landscapes
of different entities. Immune evasion has also emerged as another
oncogenic mechanism in PTCL. Programmed death (PD) ligand 1
(PD-L1) is expressed at variable frequencies,14–17 suggesting that
PD-1 blockade may represent an efficient therapy in some
patients; however, since PD-1 also acts as a tumor suppressor
which is inactivated in a fraction of PTCL, PD-1 checkpoint
inhibition may also potentially lead to unwanted effects.18,19
Constitutive genetic background may confer susceptibility to
PTCL development, as suggested by HLA associations to
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Table 1
Main nodal and extranodal mature T-cell neoplasms according to the 2017WHO classification of lymphomas, with summary of their main
characteristic (cell of origin, immunophenotype and genetic alterations) and novelties in comparison to the previous edition).
Mature T-cell






Lymphoma of mature follicular
helper T cells (TFH), the
prototypic and largest entity in
the spectrum of nodal
lymphomas of follicular helper





with T follicular helper
phenotype)
TFH cell Tumor cells: CD3+, CD4+,
TCRab+, CD10+ (50-70%),
most cases PD1+, ICOS+,
CXCL13+, BCL6+
FDC expansion
Scattered B blasts, often EBV
+









CARD11, VAV1 . . . mutations
(a few % each)
Follicular T-cell lymphoma Formerly classified as a variant
of PTCL-NOS; now classified
as an entity in the spectrum
of nodal TFH lymphomas
TFH cell Tumor cells: same as AITL with
usually strong TFH phenotype
No FDC expansion outside
follicles
Scattered B blasts, often EBV
+
Same as AITL but no IDH2
mutations
SYK-ITK fusion in ∼20%
Nodal peripheral T-cell
lymphoma with T follicular
helper phenotype
Formerly not identified as an
entity and included in PTCL-
NOS.
TFH cell Tumor cells: CD3+, CD4+,
TCRab+, positive for at least
2 TFH markers










including in all cases the
presence of “hallmark” cells,
cohesive and sinusoidal
growth
activated T cells CD30+ (100% of the cells), ALK
+, EMA+, CD25+, often





ALK fusion resulting from t(2;5)
(∼80% cases) (NPM-ALK) or t










features and clinical outcome.
CD30+ (100% of the cells),
ALK-, EMA+/, CD25+,
often CD3- with variable loss
of other T-cell antigens, CD4
+/, frequent cytotoxic profile





mutations in genes of the
JAK-STAT signaling (STAT3,
JAK1..) in ∼30% of cases
Peripheral T-cell lymphoma,
not otherwise specified
Requires the exclusion of a TFH
immunophenotype.
Molecular subsets defined on
the basis of gene expression
signatures and expression of
Th1 versus Th2 transcription
factors, may be clinically
relevant but are not yet
advocated to be assessed in
diagnostic practice.
Activated mature T cell, mostly
CD4+ central memory type,
Th1 or Th2
CD3+, CD4+>> CD8+, mostly
ab T cells, frequent aberrant
phenotype with especially loss
of CD5 and/or CD7.
A subset has a cytotoxic
profile (TIA1+, GrB+/, Perf
+/), CD8+ or CD4-/CD8-.
Two additional molecular
subsets according to
expression of GATA3 or





mutation of genes in DNA
methylation; PTCL-GATA3
harboring frequent loss/







Activated NK cell (>70%)> Tgd












mutations (up to 30%)
TP53 mutations
deletions in PRDM1, HACE1,
CDKN2A/B,
Postulated pathogenic role of
EBV
(continued )
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Formerly type I enteropathy-
associated T-cell lymphoma,




CD3+, CD5-, CD7+, CD4-/CD8-,
activated cytotoxic profile
(TIA1+, GrB+, Perf+), CD56-,
CD30+/, CD103+, EBV-
HLA association: DQ2-DQ7.
Frequent gains in 9q31.3
Mutations in JAK1 (20%–
50%), JAK3 (10%), STAT3





Formerly type II enteropathy-
associated T-cell lymphoma;
considered as a separate
entity due to lack of









CD3+, CD5-, CD7+, CD4-/CD8
+, CD56+, activated cytotoxic
profile (TIA1+, GrB+, Perf+),
CD30-, CD103+, EBV-
no reported HLA association
Mutation/deletion in SETD2
(∼90% SETD2 inactivation),






New provisional entity to
designate clonal but indolent
lymphoproliferative disorders
of the gastrointestinal tract; a
variety of immunophenotypes
may be encountered; some
cases may progress to overt
lymphoma
mature T cell, likely of intestinal
mucosa origin
CD3+, CD103-, CD4+ or CD8+,
CD56-, cytotoxic profile for
CD8+ cases, Tab+, low ki67
proliferation index, EBV-
JAK2-STAT3 fusion in CD4+
cases
STAT3 SOCS1 TET2 DNMT3A
KMT2D mutations




Mature gd T>>ab T cell of
the innate immune system
CD3+, CD5-, CD56+/, CD4-/






Mutations in SETD2 (∼35%),




Limited to cases of ab
derivation; may be associated
to autoimmune disorders;
good prognosis
Mature ab cytotoxic T cell CD3+, TCRab+, CD5-, CD8+,
CD56-, cytotoxic profile (TIA1




anaplastic large cell lymphoma




Activated T cell CD30+ (100% of the cells),
ALK-, EMA+/, CD25+,
often CD3- with variable loss
of other T-cell antigens, CD4
+/common cytotoxic (TIA1+,
Perf+, GrB+) profile, EBV-
No rearrangement of ALK,
DUSP22 or TP63 genes;
mutations in STAT3/JAK1/
SOCS3/STAT5B/ SOCS1
(50%) and in epigenetic
modifiers (KMT2D/C, CHD2,
CREBBP, . . . ) (∼70%)
EBV = Epstein-Barr virus, GrB = granzyme B, Perf = perforin.
(2020) 4:5 www.hemaspherejournal.comenteropathy-associated T-cell lymphoma. This was also demon-
strated by the recent finding of germline HAVCR2 mutations
altering TIM-3 in subcutaneous panniculitis-like T-cell lympho-
mas with hemophagocytic-lymphohistiocytic syndromes.20
Cell of origin is a major determinant of PTCL biology.
Neoplasms of innate lymphoid cells (NK, NK-like/T and gd T-
cells) are predominantly extranodal, cytotoxic and highly
aggressive. Lymphomas of the adaptive immune system (derived
from ab CD4+ or CD8+ T-cells) constitute the majority of PTCL
and often involve lymph nodes.Nodal lymphomas of T follicular helper (TFH)
derivation
Derivation from CD4+ TFH cells is the defining feature of the
largest group of nodal lymphomas which includes angioimmu-3
noblastic T-cell lymphoma (AITL), follicular T-cell lymphoma
and nodal lymphoma with a TFH phenotype. AITL which
typically manifests with systemic symptoms and biological
abnormalities, consists of a polymorphous infiltrate comprising
TFH neoplastic cells within an abundant polymorphous
microenvironment associated with proliferation of venules and
follicular dendritic cells.21 In addition to sharing a TFH
immunophenotype and gene expression signature,22 these
lymphomas disclose a homogeneous mutational landscape that
recapitulates a multi-step oncogenic process. This typically
consists of epigenetic deregulation such as TET2 ± DNMT3A
mutations (in up to 80% of the cases), often occurring at early
stages in hematopoietic progenitors.3,13 In addition, there are
second-hit mutations including a hotspot RHOAG17V mutation
(50%–80% of cases) and other gain-of-function mutations
targeting the TCR signaling pathway (PLCG1, CD28, PIK3
components, CARD11).7,10 Moreover, fusions involving SYK,
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Figure 1. Angioimmunoblastic T-cell lymphoma (A) comprising the presence of scattered neoplastic cells with an abundant cytoplasm (arrows) which by
immunohistochemistry (B) show cytoplasmic granular staining with an antibody specific for the R172K variant of IDH2, reflecting an IDH2 mutation.
Bachy et al Controversies in the Treatment of Peripheral T-cell LymphomaITK, CD28, CTLA4 or CD28 and ICOS are detected at lower
frequency.23 In addition, IDH2R172 mutations resulting in
production of an oncometabolite are found in 25-30% of AITL
(Fig. 1).24 Transgenic mouse models with expression of
RHOAG17V in the T-cell compartment demonstrated the role
of RHOAG17V in TFH differentiation and in inducing autoim-
munity.25 However, additional TET2 inactivation is required for
lymphoma development, and these mouse tumors are dependent
on ICOS/PIK3/MTOR signaling.26
Anaplastic large cell lymphomas (ALCL)
ALCL have in common several features: large-cell anaplastic
morphology, strong CD30 expression and frequent phospho-
STAT3 activation (Fig. 2, panels A–C). Systemic cases such as
anaplastic lymphoma kinase (ALK)-positive and ALK-negative
represent 15% to 20% of non-cutaneous PTCL. ALK-positive
ALCL occurs mainly in children and young adults having an
excellent overall prognosis. ALK fusion proteins resulting from
the fusion of ALK to various gene partners, most commonly
NPM1 (nucleophosmin), drive lymphomagenesis by several
mechanisms, among which activation of STAT3 plays a
prominent role.27 ALK-negative ALCL tend to occur in older
patients and are genetically heterogeneous. Cases with rear-
rangement of the DUSP22 locus@6p25 (one third of the cases)
have unique molecular features – lack of STAT3 activation, DNA
hypomethylation and an immunogenic phenotype.17 They also
frequently harbor a hotspot MSCE116K mutation in the musculin
gene driving cell cycle progression that can be targeted with BET
inhibitors.28DUSP22-rearranged ALCL have a good outcome in
most series.29–32 In contrast, the rare ALK-negative ALCL with4
TP63 rearrangements has very poor outcomes.30 A subgroup of
ALK-negative ALCL have STAT3 activation resulting from
rearrangements of other tyrosine kinase genes such as TYK2,
ROS1, FRK or activating mutations of JAK or STAT3.17 In
addition, downregulated Wiskott-Aldrich syndrome protein
(WASP) was recently identified as another oncogenic pathway
in ALCL.33
Breast implant-associated (BIA) ALCL, a peculiar form of
ALK-negative ALCL, is a rare complication of breast implants
(Fig. 2, panels D-E).34 Most cases confined to the periprosthetic
effusion and capsule (seroma or in situ lymphoma) have excellent
outcomes; a minority of patients present with a tumor mass,
which is an adverse prognostic factor. BIA-ALCL does not harbor
recurrent translocations found in other ALK-negative ALCL;
conversely, activation of STAT3 is common and recurrent
mutations of STAT3, JAK1, or SOCS1 have been reported.35
Chronic inflammation elicited by the texture of the implant,
silicone-derived products or bacteria adherent to the prosthesis
likely play a role in triggering polyclonal lymphocyte activation
and expansion through the release of cytokines like IL6 and
IL10.36 Supervening genetic alterations would represent an
additional step in the transformation process to a malignant
monoclonal proliferation.Peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS)
PTCL-NOS is a heterogeneous group of cases not fulfilling the
criteria for more specific entities. Some cases are associated with
Epstein-Barr virus infection. Gene expression profiling has
unraveled molecular subgroups with differential expression of
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Figure 2. Anaplastic large cell lymphomas. (A–C) Lymphohistiocytic variant of ALK-positive ALCL comprising a polymorphous infiltrate rich in histiocytes and
plasma cells with large atypical cells (arrows) which are strongly positive for CD30 (B) and show a cytoplasmic staining for ALK (C) indicative of a translocation other
than NPM-ALK. (D-E) Breast implant-associated ALCL: in situ lymphoma on the inner surface of the periprosthetic capsule (D), comprising numerous large
anaplastic cells (E).
(2020) 4:5 www.hemaspherejournal.commaster T helper 1 (TH1) or TH2 cell-associated transcription
factors (TBX21 and GATA3, respectively) and their associated
target genes. GATA-3-positive PTCL-NOS and those with a
cytotoxic phenotype are associated with worse outcomes
compared with TBX21-positive tumors.37,38 Genetically,
PTCL-GATA3 exhibit higher genomic complexity with frequent
loss or mutation of tumor suppressor genes targeting the
CDKN2A/B-TP53 axis and PTEN/PI3K pathway. PTCL-TBX2
have fewer copy number aberrations and are enriched in
mutations of genes regulating DNA methylation.39Frontline treatment
The standard of care for the last 30 years has been
cyclophosphamide, doxorubicin, vincristine, prednisolone
(CHOP) with or without additional etoposide (CHOEP). A
meta-analysis of the outcome of PTCL treated with anthracy-
cline-based regimens demonstrated a 5-year overall survival of
only 36.6%.40 Attempts have been made to improve on this poor
outlook by: (i) adding newer drugs to the CHOP backbone
(alemtuzumab, romidepsin, brentuximab vedotin); (ii) intensify-
ing the regimen (DA-EPOCH); (iii) developing alternative
regimens (eg, gemcitabine-based combinations).Alternative regimens to CHOP
Retrospective data collection from the German High Grade
NHL study group trials, in which a small number of PTCL were
included, suggested benefit for addition of etoposide (CHOEP)5
for younger patients, especially those with ALCL.41 A single arm
phase 2 study investigated the use of DA-EPOCH (etoposide,
prednisolone, vincristine, cyclophosphamide and doxorubicin).42
This small trial (41 patients) reported after very short follow-up
(median 24 months) showed favorable results with 2-year
progression free survival (PFS) and overall survival (OS) of 53%
and 73%, respectively. A larger study is needed to confirm these
results. The European Society of Medical Oncology guidelines
recommend dose dense CHOEP as initial chemotherapy for
younger patients with PTCL-NOS.43
Prospective randomized trials failed to show superiority over
standard CHOP for addition of alemtuzumab (ACT trial)44
or use of an alternative regimen like GEMP (gemcitabine,
methylprednisolone, cisplatin) (CR rate of 62% with CHOP
compared with 46% for GEMP).45 The results of CHOP +
romidepsin versus CHOP alone are awaited. A randomised trial
comparing CHOP with CMED (cyclophosphamide, methotrex-
ate, etoposide, dexamethasone) in 217 patients with PTCL-NOS
in a single center in South America,46 showed improved CR rate,
PFS and OS. However, there were a number of difficulties with
the interpretation of the data since there was no central review of
pathology or imaging, the patients were young and the control
arm did not receive high dose therapy.
The only clearly positive study was ECHELON-2, a large
randomized trial in 452 CD30+ PTCL comparing CHOP (6
courses) with CHP (i.e. with vincristine omitted) combined with
brentuximab vedotin (BV).47 The results showed superior PFS for
the BV-CHP combination. However, 75% of the patients in the
study had ALCL and the benefit for the BV-CHP regimen was not
HEMASPHERE-2020-0108; Total nos of Pages: 12;
HEMASPHERE-2020-0108
Bachy et al Controversies in the Treatment of Peripheral T-cell Lymphomastatistically significant in the non-ALCL subtypes (72 PTCL-NOS
and 54 AITL). Thus, there is insufficient evidence to recommend
BV-CHP for CD30+ non-ALCL PTCL.
CNS involvement is rare (1.5% at presentation, 4%–8% at
relapse) inPTCL-NOSandAITL48:CNSprophylaxis isnotusually
indicated, but it may be considered when >1 extranodal site is
involved, given that risk of CNS relapse rises to 10% to 20%.
Certain sites of disease such as paranasal sinus, skin, testis and
gastro-intestinal tract are also associated with higher risk.
Extranodal NK/T-cell lymphoma merit a different approach:
although a detailed description of the first line treatment in these
rare disease entities is beyond the scopes of this paper, it is
important to note that they seem to be quite sensitive to
asparaginase-based regimens. In particular, the dexamethasone,
methotrexate, ifosfamide, L-asparaginase, etoposide (SMILE)
regimen has brought better outcomes than any anthracycline-
containing regimen in this context.49 More recently, the
dexamethasone, cisplatin, gemcitabine and pegaspargase
(DDGP) regimen has demonstrated better efficacy over SMILE,
now confirming its role as the standard first line approach in NK/
T-cell lymphoma.50Front line treatment: consolidation
International guidelines now recommend that consolidation
with high dose therapy and ASCT in first remission should be
considered for patients with chemo-sensitive PTCL-NOS, AITL
and other rare subtypes, but not for ALK-positive ALCL.43 Both
retrospective and prospective studies have suggested that patients
may benefit from this strategy by prolonging PFS (3-year PFS of
40%–50%) and OS.51 A systematic review and meta-analysis of
27 publications covering 1368 patients reported a PFS rate of
33% (95% confidence interval 14%–56%) for the prospective
studies analyzed.52 Results from the Comprehensive Oncology
Measure in Peripheral T-cell Lymphoma Treatment study
(COMPLETE study) have recently been reported. In this
observational study that identified 119 patients with nodal
PTCL in first CR, 36 underwent ASCT and 83 did not. In
multivariate analyses, ASCT was independently associated with
improved OS.53 However, these studies are inherently biased by
the selection of better outcome patients. About one-third of
patients in prospective trials failed to receive the planned ASCT
either because they did not achieve a remission or due to early
progression.51 Furthermore, some registry studies failed to show
an advantage for ASCT, particularly if the analysis focused on
patients in CR after induction. In a French study of over 500
patients, the 57% responders had the same outcome regardless of
whether they received ASCT or not, with a 5-year OS and PFS of
60% and 45%, respectively, for both groups.54 Thus, there is still
some controversy on the role of ASCT in first remission although
it has been recognized that for some subtypes such as AITL this
may be more beneficial.
Allogeneic SCT (alloSCT) is not recommended frontline other
than for very rare subtypes with extremely poor outcome, such as
hepatosplenic T cell lymphoma.43Positron emission tomography (PET) in PTCL
18F-fluorodeoxyglucose (FDG) PET scan is not applied
routinely for disease staging, although it has proven to be
helpful in detecting FDG-avid nodal or extranodal lesions that
can be missed by a CT scan evaluation.55 PET positivity found at
the end of induction treatment56,57 and in patients who have6
received ASCT is a strong predictor of reduced survival58 and this
seems particularly true for PTCL-NOS and AITL patients. On the
contrary, uncertainty still exists on the role of interim PET
evaluation during induction treatment. Some published experi-
ences document that a negative interim scan (described in terms
of the International Harmonization Project or applying the
Deauville 5-point scale) has a favorable impact on OS59 and
maybe on progression-free survival (PFS),60 possibly because
PET-negative patients were more likely to receive consolidation
therapy which contributed to their better survival rates. On the
other hand, others show a lack of any prognostic value.56
Major controversies:
Who should get etoposide? Should non-ALCL CD30+ PTCL
all get brentuximab vedotin? Who should get ASCT in first
remission (in terms of disease subtype) and does level of
response matter (CR vs PR)?The treatment of elderly patients
PTCL remain a group of diseases most commonly affecting the
elderly with a median age at onset of 67 years.61 Although some
subtypes target younger age groups (eg, ALK-positive ALCL,
median age of 41 years), the most frequent subtypes of PTCL-
NOS, TFH-PTCL and AITL remain more common in patients
over 60 years. However, patients in the older age group and those
who have comorbidities and poor performance status are often
under-represented in clinical trials. There is therefore very limited
data available regarding the elements on which to base treatment
decisions.Registry data: the impact of age and performance
status
Several epidemiological studies using registry data have all
suggested a negative impact of age and comorbidities on patient
outcomes. In the Swedish registry, two-thirds of patients were
over the age of 60 years and of 694 patients 38% had significant
comorbidities. A Charlson comorbidity score equal to or greater
than 2 was associated with inferior PFS and OS, and even limited
comorbidity had an impact on survival.62 In the recent refinement
of the T-cell International Prognostic Index (IPI), performance
status was the most important independent predictor of
outcome.63 In a larger study (775 patients) based on data from
Sweden, US and Canada, the outcome was stratified according to
event-free survival at 24 months, showing dismal survival for the
two-thirds of patients who progressed within 2 years (OS 11% at
5 years) as compared to those who were event-free (OS 78% at
5 years). Age over 60 had a negative impact on the good-risk
group compared to younger patients. Other trials have also
consistently shown age >60 to be an independent risk factor.64
Results may also be confounded by the fact that this group of less
fit patients will rarely benefit from a consolidation with ASCT in
first remission. In the ACT-1 trial,44 patients up to 65 years were
initially consolidated with ASCT; however, due to treatment-
related toxicity, the age limit for inclusion into this trial had to be
reduced to 60 years.CHOP or not?
CHOP remains the standard of care in the elderly, but it is well
recognized that patients are more vulnerable to associated
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(2020) 4:5 www.hemaspherejournal.comtoxicities. Clearly, omitting anthracyclines may have advan-
tages in reducing cardiac toxicity, which is an age-related risk.
The utility of including anthracyclines has been questioned,
with some reports showing no benefit. For example, the
International Peripheral T-cell and Natural Killer/T-cell
Lymphoma Study failed to show an advantage for the use of
anthracycline-containing initial chemotherapy regimen in
PTCL-NOS and AITL subtypes.65 Whilst in a series of 300
PTCL patients from the Mayo Clinic, improved PFS and OS
were reported with anthracycline-containing regimens, even
when the analysis was restricted to PTCL-NOS and AITL
subtypes.66 In a retrospective review of German study group
trials, the addition of etoposide to CHOP did not show
improved results in patients over 60 years of age.41 The Swedish
study reported that patients over 75 years old had no difference
in outcome between those using curative multi-agent chemo-
therapy and low intensity regimens, with similar OS when
adjusted for comorbidity index.62 A registry study from
Thailand of 127 patients over the age of 60 years showed that
two-thirds of patients received multi-agent chemotherapy,
dropping to 34% in the over 75 year age group. With relatively
short follow-up (17 months), in this study 2-year PFS and OS
were 38% and 48%, respectively. Older age, poor performance
status and absence of multi-agent chemotherapy were all
associated with poor outcome in multivariable analysis. The
choice of chemotherapy remained significant even after adjust-
ing for age, comorbidity, performance status and IPI. The
authors concluded that multi-agent chemotherapy (largely
CHOP) should be given whenever possible and that a
comprehensive geriatric assessment is useful.67 A Korean study
in 44 patients over 70 or between 65 and 70 but with co-
morbidities (median age 74) gave very similar outcome data.
Patients received dose-attenuated CHOP (cyclophosphamide:
562.5mg/m2, doxorubicin: 37.5mg/m2, vincristine: 1.4mg/m2,
and prednisolone: 100mg for five days; 25% reduced dose of
cyclophosphamide and doxorubicin) as first-line therapy. The
overall response rate was 61%, and 2-year PFS and OS were
37% and 47%, respectively. Three-quarters of patients
experienced grade 3/4 neutropenia and there were 6 treat-
ment-related deaths: although efficacy is not apparently
reduced compared to full-dose CHOP, the toxicity remains
significant in this age group.68Elderly patients in clinical trials
Data from prospective randomized trials are scarce. The ACT-
2 trial included 116 pts aged 61-80 years (median age 69 years)
that were randomized to either CHOP or CHOP + alemtuzumab.
Adding alemtuzumab to CHOP increased response rates but did
not improve survival due to treatment related toxicity. However,
feasibility of standard CHOP with a 3-year OS of 56%
demonstrated the tolerability and efficacy of anthracyline-based
treatment in the elderly.69 In the ECHELON-2 trial, patients with
CD30+ PTCL up to the age of 80 were to receive either CHOP or
CHP + BV: 139 patients older than 65 years were included,
without experiencing undue toxicity. Therefore, anthracycline-
based polychemotherapy remains the standard treatment for this
group of patients.47
If anthracycline-based chemotherapy is not deemed feasible,
there may be merit in exploring alternative treatment regimens
in individual cases. Gemcitabine-based therapy can be effective
and less toxic, as seen in diffuse large B-cell lymphoma
with the use of R-GCVP.70 Monotherapy with novel agents,7
such as BV in ALCL, romidepsin, praletrexate and duvelisib,
may have activity with less toxicity in carefully selected
patients.
Major controversies:
Lack of data and randomized trials to indicate clearly the most
suitable first-line approach. Anthracyclines or not? Full dose
or dose-attenuated regimens? Are any older patients eligible
for ASCT?The conventional approach in relapsed and
refractory patients
Disease refractoriness or relapse occurs in nearly two-thirds of
patients with PTCL, except ALK-positive ALCLwhichwill not be
specifically discussed in this section. Median PFS and OS are
known to be extremely poor in this setting, not exceeding 4 or 7
months, respectively.71 Ofmain concern is the fact that results are
only marginally better for patients who receive chemotherapy at
relapse (3.7 months for PFS and 6.7months for OS) questioning a
pure palliative approach for patients who cannot be offered a
transplant procedure.Approved single-agents
For the last 2 decades, phase 2 clinical trials have demonstrated
that overall response (OR) and CR rates were consistently limited
around 25% to 40% and 10% to 15% respectively for single
agent romidepsin, pralatrexate, belinostat, BV, and others.72–76
Likewise, median PFS and OS usually did not exceed 6 and 14
months in these studies. The Food and Drug Administration (but
not the European Medicines Agency) has granted approval for
romidepsin (in 2011), pralatrexate (in 2009) and belinostat (in
2014) in relapsed/refractory PTCL after at least one previous line
of treatment. Overall, all 3 agents showed similar disappointing
long-term results, but specific subtypes such as AITL seemed to
benefit the most from epigenetic modifying agents, although any
subgroup analysis needs to be interpreted cautiously. With
romidepsin used as monotherapy at a dose of 14mg/m2 at day 1,
8, 15 of 28-day cycles, OR and CR rates reached 33% and 22%
in AITL compared to 25% and 15% in PTCL in general. With
belinostat used as monotherapy at a dose of 1000mg/m2 from
day 1 to 5 of 21-day cycles, OR reached 45% in AITL compared
to 25% in PTCL-NOS. Although not approved in Europe,
romidepsin and belinostat can be used in some countries based on
a compassionate use program. Pralatrexate, administered
intravenously at the dose of 30mg/m2/week for 6 weeks,
followed by 1 week of rest, until progressive disease or
unacceptable toxicity, has showed significant activity in PTCL-
NOS and ALCL patients in the pivotal PROPEL trial, with anOR
rate of 32% and 35%, respectively.73 For this reason, it is
considered the first salvage treatment in this context of patients, if
available. Mucositis is the most relevant adverse event with
pralatrexate: vitamin B12 and folate supplementation, alongwith
dose reduction to 20mg/m2 are required in patients experiencing
drug-related mucosal toxicity.
Cyclosporine A is a therapeutic option in second or
subsequent line especially for AITL patients who are not
candidate to ASCT. A recently published review gathering 26
patients has reported an outstanding OR rate of 86% in heavily
pretreated AITL cases, including patients who had failed a
previous ASCT.77
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this paper.
Conventional chemotherapy salvage regimen
If ASCT has not been performed frontline as a consolidation
procedure, it is usually considered the standard of care for fit
patients in the relapsed/refractory setting although no study has
formally demonstrated its superiority over conventional therapy.
The optimal salvage regimen before high dose therapy and
transplant is still a matter of debate since no large randomized
trial or compelling evidence has demonstrated a clear advantage
for a peculiar regimen over another. Puig et al presented
retrospectively collected data from 40 patients with refractory
disease or in first relapse aiming for ASCT. Most patients were
treated with DHAP (cisplatin, cytosine arabinoside, dexametha-
sone) or ESHAP (etoposide, methylprednisolone, cytarabine,
cisplatin). OR rate was 63% with those regimens.78 The study
from Mikesch et al retrospectively assessed the outcome of
patients receiving either DexaBEAM (dexamethasone, carmus-
tine, etoposide, cytarabine and melphalan; n=16) vs ICE
(ifosfamide, carboplatin and etoposide; n=15) as first salvage
regimen followed by ASCT. The OR and CR rates were higher
with DexaBEAM than ICE (69% vs 20%, p=0.01; and 38% vs
7%, p=not significant) although toxicity was also more common
after Dexa-BEAM.79 The study from Yao et al reported a new
salvage regimen for patients unsuitable for high dose therapy and
ASCT combining gemcitabine, oxaliplatin and dexamethasone
(GemOD) for up to 6 courses every 21 days.80 GemOD provided
a 38% OR rate, which might appear disappointing, but
comparison with other regimen for patients fit for high-dose
therapy as in the aforementioned study from Mikesch et al is not
possible. The Royal Marsden Hospital reported an OR rate of
69% with a regimen combining gemcitabine, cisplatin and
methylprednisolone (GEMP-P) for 16 patients among who 15
were pretreated.81 To date, DHAP or DHAOx or DHAC (DHAP
in which platine is replaced by oxaliplatin or carboplatin),
ESHAP, GDP (gemcitabine, dexamethasone, cisplatin), GemOx
(gemcitabine, oxaliplatin) or ICE (ifosfamide, carboplatin,
etoposide) are the most frequently used regimen at relapse or
in refractory disease worldwide.
Role of ASCT and allogeneic stem cell transplant
(alloSCT)
Mostly retrospective studies or prospective non-randomized
trials have been reported concerning the role of ASCT and
alloSCT in PTCL. Extensive bibliography from previous reviews
is reported elsewhere and will not be part of this chapter.82–88
Except for ALK-positive ALCL and for unfit patients, the
National Comprehensive Cancer Network guidelines recom-
mend ASCT, observation or clinical trial enrollment in first-line
complete metabolic response in PTCL. The ESMO43 and the
American Society for Blood and Marrow Transplantation89
guidelines recommend ASCT for partial or complete responders.
However, recently published data from the Lymphoma Study
Association (LYSA) suggest that in routine practice, roughly half
of patients are not planned for ASCT in intention-to-treat, due to
low consensus among the community on the real benefit
associated with ASCT in first remission in the absence of
randomized trial.54 Consequently, a substantial fraction of
patients with relapsed/refractory PTCL does not undergo ASCT
in first line and might be considered for the procedure in case of8
disease sensitive to conventional chemotherapy, approved
single agents or investigational drugs. ASCT is therefore
often considered the standard of care for eligible relapsed/
refractory patients if they did not receive consolidation strategy in
first line. However, as in newly diagnosed patients, no convincing
data from randomized trials exist to support this strategy
compared to no further consolidation after conventional
chemotherapy or approved single agent like pralatrexate,
romidepsin or belinostat. Indeed, most studies on ASCT in
relapsed/refractory patients suffer from the following drawbacks:
retrospective selection bias, mixed histologies, various salvage
regimen, heterogeneous patient characteristics and response
status before ASCT.
Concerning the role of alloSCT, recent data from the AATT
trial (EudraCT Number: 2007-001052-39) in first line confirmed
that a better control of disease over ASCT is obtained at the
expense of greater toxicity, resulting in similar OS. In the
relapsed/refractory setting, data from the literature are scarce and
suffer from identical biases as for ASCT studies.
Major controversies:
Which is the best treatment to adopt for patients with PTCL
(except ALK-positive ALCL) with a relapsed/refractory
disease? Can we think about a disease-specific approach with
any of the new agents (e.g. pralatrexate in PTCL-NOS,
romidepsin versus belinostat in AITL)? Is there a role for
ASCT if patients are considered fit enough and if not
performed in first line? Can alloSCT be superior to ASCT in
relapsed/refractory patients?New experimental agents
Targeting epigenetic modifiers
PTCL harbor a multitude of genetic alterations affecting
epigenetic regulators. While the functional consequences of many
of these alterations remain poorly understood, the clinical activity
of drugs like histone deacetylase inhibitors is still intriguing:
durable responses with a median duration of 13 and up to 17
months can be achieved with belinostat and romidepsin,
respectively, leading to FDA approval.90 Unfortunately, both
belinostat and romidepsin showed overall response rates of only
roughly 25% in relapsed/refractory PTCL and predictive
biomarkers of response do not exist. However, taking advantage
of their potential activity, multiple combination strategies
including HDAC inhibitors are currently being tested in clinical
trials, including a front-line phase 3 trial of romidepsin + CHOP
(NCT01796002).91 Furthermore, novel derivatives of HDAC
inhibitors like the alkylating deacetylase inhibitor molecule
tinostamustine (EDO-S101) were developed recently and have
now entered clinical trials including PTCL (NCT02576496).92
The high incidence of mutations affecting the TET family of
DNA methylcytosine hydroxylases with subsequently increased
DNA methylation, provides a rationale for hypomethylating
agents (HMA) like 5-azacytidine. Indeed, treatment with 5-
azacytidine induced sustained responses in AITL.93 Further
clinical data will be needed, though, to assess the predictive role
of mutations affecting TET2, IDH1/2 orDNMT3A for HMA, as
reported for MDS and AML.94–96 Furthermore, novel combi-
nations are on their way: in a recent phase 1 combination trial of
5-azacytidine and romidepsin, O’Connor et al reported OR and
CR rates of 73% and 55%, respectively.97
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epigenetic modifiers and the clinical activity of HDAC inhibitors
and hypomethylating agents is intriguing. However, as these
drugs have pleiotropic effects, patient stratification and develop-
ment of predictive biomarkers of response remain a major
obstacle and clinical data on the safety and efficacy of
combination strategies need to be awaited.Emerging immunotherapeutic strategies
PTCL are commonly infiltrated by a variety of non-neoplastic
immune cells, but sufficiently evade anti-tumor immune responses.
From a therapeutic perspective, novel strategies targeting distinct
mechanisms of immune-evasion are currently emerging.
The development of checkpoint inhibitors, targeting the
interaction of PD-1 and PD-L1/PD-L2 with subsequent repres-
sion of T cell activation has revolutionized therapeutic options in
multiple malignancies.98 In PTCL, increased expression of PD-L1
has been described in both malignant and stromal cells across
various subtypes, suggesting therapeutic checkpoint-inhibition.
Indeed, partial responses in PTCL were described in a phase 1b
study with nivolumab.99 However, PD-1 was also recently
described as a potential haploinsufficient tumor-suppressor and
cases of rapid disease progression after PD-1 inhibitor therapy
have been described, particularly in ATLL.19,100 Thus, as robust
clinical data are scarce, results of clinical studies including PD-1
inhibition are urgently needed to clarify the role of PD-1
checkpoint-inhibitors in T cell lymphomas.
Further targetable mechanisms of immune evasion recently
emerged in TCL: CD47, a glycoprotein of the immunoglobulin
superfamily providing a “don’t eat me” signal by binding to signal
regulatory proteina (SIRPa) onmacrophages has been found to be
overexpressed in PTCL-NOS and cutaneous T cell lymphomas.101
Therapeutic antibodies have been designed to interrupt the CD47-
SIRPa interaction. Of these, the CD47 decoy receptor signal
regulatory protein aFc (SIRPaFc; TTI-621) recently showed
activity in patients with Sézary syndrome.102 Similarly, the killer
cell immunoglobulin-like receptor KIR3DL2 was found to be
expressed in CTCL and IPH4102, a first-in-class anti-KIR3DL2
monoclonal antibody recruiting and activating NK cells showed
activity in patients with relapsed or refractory CTCL.103 Notably,
high expression levelswere also found in subtypes of PTCLand the
efficacy of IPH4102 in PTCL is currently being tested in a multi-
cohort, phase 2 trial (TELLOMAK).
Ultimately, concepts for chimeric antigen receptor (CAR) T
cells are being developed for PTCL. However, as pan T cell
aplasia causes severe immunodeficiency, these concepts are
challenged by the lack of specific antigens discriminating
malignant and normal T cells. The mutually exclusive expression
pattern of the T cell receptor b-chain constant domains 1 and 2
(TRBC1 and TRBC2), though, might be a promising approach to
target neoplastic T cells harboring either TRBC1 or TRBC2while
preserving a substantial proportion of normal T cells.104
Targeting SYK and phosphatidyl-inositol 3-kinase
(PI3K) pathways
The SYK signaling pathway plays a role in oncogenic
transformation: experimental data suggest that SYK is an
oncogenic driver in subsets of T cell lymphomas, being highly
expressed (> 90% of cases of systemic and cutaneous ALCL,
AITL, PTCL-NOS, mycosis fungoides) in its native form or
uncommonly as a fusion protein with ITK.1059
Cerdulatinib is an orally available, ATP-competitive inhibitor
of SYK, JAK1, JAK3 and Tyk2, whose efficacy has been
demonstrated in T cell lines of ATLL.106 Its role in relapsed/
refractory PTCL and cutaneous T cell lymphomas (CTCL) has
been evaluated in a phase 2a study in which it was administered
orally at the dose of 30mg bid in 28-day cycles until progression
or intolerance. In 41 PTCL patients, the treatment produced an
overall response rate of 34% according to the Lugano criteria
(CR in 27% and PR in 7% of cases), whereas in 27 evaluable
patients with CTCL the overall response rate was 26%, with a
CR in 7% and a PR in 19% of cases. Overall responses were seen
across multiple histologies, mainly in ATLL (33%), TFH/AITL
(57%, with 50% of CR), ALCL (33%).107
PI3K inhibition blocks mitogen and prosurvival signals from
tumor and microenvironment cells and concomitantly activates
an anti-lymphoma immune response.
Duvelisib, an oral dual inhibitor of the isoforms PI3Kg and
PI3Kd, was applied as single agent in a phase 1 trial involving 16
PTCL and 19CTCL patients with relapsed/refractory disease. The
drugwas administered on a dose-escalation basis, starting from25
mg bid up to 100mg bid on a 28-day cycle and the maximum
tolerated dose was 75mg bid. In the PTCL population, the overall
response rate was 50%, with 3 CR and 5 PR, all occurring within
the first 2 to 4 months of treatment. Responses were seen across
multiple histologies, including PTCL-NOS, and AITL.MedianOS
and PFS were 8.4 and 8.3 months, respectively. In the CTCL
population, 6 patients obtained a PR, all within 4 months since
treatment inception.Median PFSwas 4.5months, with 1-year PFS
and OS being 26.5% and 78.9%, respectively. Transaminase
elevation was the most relevant adverse event (57%of cases), with
grade 3–4 toxicity described in 40% of patients.108
Based on these results and on an in vitro documented
synergism, a phase 1 trial of duvelisib+romidepsin (arm A)
and duvelisib+bortezomib (arm B) was initiated in relapsed/
refractory PTCL and CTCL patients. Duvelisib was given at 25
mg bid, 50mg bid or 75mg bid, romidepsin at 10mg/m2 on days
1, 8, 15 and bortezomib at 1mg/m2 on days 1, 4, 8 and 11, on 28-
day cycles. In expansion cohorts, duvelisib was given with
romidepsin at 75mg bid and at 25mg bid with bortezomib.
Thirty-eight patients in arm A and 31 in arm B were evaluable for
response: the combination duvelisib+romidepsin produced an
overall response rate of 55% (59% in PTCL and 45% in CTCL
patients), with a CR rate of 24% (33% in PTCL and 0 in CTCL
patients). AITL and PTCL-NOS appeared as the most sensitive
entities, with 75% and 64% of OR rate, and 63% and 36% of
CR rate, respectively. The combination duvelisib + bortezomib
yielded an OR rate of 35% (44% in PTCL and 27% in CTCL
patients), with a CR rate of 13% (25% in PTCL and 0 in CTCL
patients). Incidence of transaminase elevation was interestingly
much lower than with single agent duvelisib.109
Major controversies:
Which single agent is likely to be more promising? Can we
think about combining experimental agents with approved
target therapies?Conclusions
PTCL are rare and heterogeneous diseases: their classification
is still evolving, given the significant amount of knowledge in
terms of biomolecular mechanisms gained in the last few years.
First-line antracycline containing regimens are currently the
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neous. ASCT is part of the frontline approach to PTCL, even
though its consolidative role may be weakened in complete
responders after induction. On the other hand, it is important to
note that the majority of PTCL are diagnosed in elderly patients,
for whom a recognized standard of care is still lacking. Newly
approved drugs are capable of inducing relevant OR and CR
rates in relapsed and refractory disease, although response
durations are limited over time. This is why new molecules are
eagerly needed. More specifically, multiple novel concepts
targeting immune-escape mechanisms and key pro-survival
pathways are emerging for T cell lymphomas, needing to be
tested in clinical trials. Alongside, thorough correlative studies
are warranted to understand mechanisms of response and
resistance and to incorporate these approaches into rational
combination strategies.Disclosures
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